Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.

The UK Health Security Agency has warned that it could become 'serious if left untreated' - signs and symptoms to learn ...

The bacteria can cause severe complications, such as rheumatic fever, and possible damage to the kidneys, liver, or heart, along with other infections ...

The US company’s two simultaneous trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of ...

Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.

Incyte's experimental skin disease drug met the main goal of two separate late-stage trials, but data showed that it was not as effective as in its prior studies, sending the drugmaker's shares down ...

Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...

The Wilmington, Del., biopharmaceutical company said the study data support planned worldwide regulatory submissions for povorcitinib for the treatment of hidradenitis suppurativa, which can lead to ...

Experts have warned that an unusual sign in the fingertips could be a symptom of one of the UK’s most common cancers. This ...